2-(4-cyanophenyl)-4-(3,4-methylenedioxyphenyl)-N-1-hydroxy-5-(2-pyridyl)-imidazole | 301836-33-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 2-(4-cyanophenyl)-4-(3,4-methylenedioxyphenyl)-N-1-hydroxy-5-(2-pyridyl)-imidazole
• 英文别名: 4-(4-benzo[1,3]dioxol-5-yl-1-hydroxy-5-pyridin-2-yl-1H-imidazol-2-yl)benzonitrile；4-[4-(1,3-Benzodioxol-5-yl)-1-hydroxy-5-pyridin-2-ylimidazol-2-yl]benzonitrile
• CAS: 301836-33-9
• 化学式: C₂₂H₁₄N₄O₃
• 分子量: 382.378
• InChiKey: GBUOMORWOFNROB-UHFFFAOYSA-N

物化性质

• 沸点：
  650.2±65.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  93.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(4-cyanophenyl)-4-(3,4-methylenedioxyphenyl)-N-1-hydroxy-5-(2-pyridyl)-imidazole 生成 4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzoic acid
  参考文献：
  名称：

  Triarylimidazoles

  摘要：

  式（I）的化合物或其药用盐：其中R1、R2和R3是各种取代基；X1和X2中的一个是N或CR'，另一个是NR'或CHR'，其中R'是氢、OH、C1-6烷基或C3-7环烷基；或者当X1和X2中的一个是N或CR'时，另一个可以是S或O；以及它们作为药物的用途。

  公开号：

  US06465493B1
• 作为产物：
  描述：

  2-hydroxyimino-2-(2-pyridyl)-(2,3-methylenedioxy)-acetophenone 、 4-氰基苯甲醛 在 ammonium acetate 作用下， 以 溶剂黄146 为溶剂， 反应 36.0h， 生成 2-(4-cyanophenyl)-4-(3,4-methylenedioxyphenyl)-N-1-hydroxy-5-(2-pyridyl)-imidazole
  参考文献：
  名称：

  Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)

  摘要：

  Screening of our internal compound collection for inhibitors of the transforming growth factor beta1 (TGF-beta1) type I receptor (ALK5) identified several hits. Optimization of the dihydropyrroloimidazole hit 2 by introduction of a 2-pyridine and 3,4-methylenedioxyphenyl group gave 7, a selective ALK5 inhibitor. With this information, optimization of the triarylimidazole hit 8 gave the selective inhibitor 14, which inhibits TGF-beta1-induced fibronectin mRNA formation while displaying no measurable cytotoxicity in the 48 h XTT assay.

  DOI：

  10.1021/jm010493y

文献信息

• [EN] TRIARYLIMIDAZOLES<br/>[FR] TRIARYLIMIDAZOLES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2000061576A1

  公开（公告）日：2000-10-19

  Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2 and R3 are various substituent groups; and one of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O; and their use as pharmaceuticals.

  公式（I）的化合物或其药学上可接受的盐：其中R1、R2和R3是各种取代基；X1和X2中的一个是N或CR'，另一个是NR'或CHR'，其中R'是氢、OH、C1-6烷基或C3-7环烷基；或者当X1和X2中的一个是N或CR'时，另一个可以是S或O；以及它们作为药物的用途。
• METHOD FOR PREPARING OSTEOBLASTS AND OSTEOBLAST INDUCER
  申请人：Kyoto Prefectural Public University Corporation

  公开号：EP3133149A1

  公开（公告）日：2017-02-22

  An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) cAMP inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts.

  本发明的目的是提供一种制备成骨细胞的方法，该方法适用于骨缺损修复或骨吸收、骨折、骨质疏松症或类似疾病的治疗，且不会引起癌症风险。为了解决这个问题，本发明提供了一种制备成骨细胞的方法，该方法包括在培养基中培养哺乳动物分化的体细胞，培养基中至少有一种选自以下组的化合物：(1)他汀化合物；(2)酪蛋白激酶1抑制剂；(3)cAMP诱导剂；(4)组蛋白甲基转移酶抑制剂，以将体细胞转化为成骨细胞。
• Method for preparing osteoblasts and osteoblast inducer
  申请人：KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION

  公开号：US11174464B2

  公开（公告）日：2021-11-16

  An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) cAMP inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts.

  本发明的目的是提供一种制备成骨细胞的方法，该方法适用于骨缺损修复或骨吸收、骨折、骨质疏松症或类似疾病的治疗，且不会引起癌症风险。为了解决这个问题，本发明提供了一种制备成骨细胞的方法，该方法包括在培养基中培养哺乳动物分化的体细胞，培养基中至少有一种选自以下组的化合物：(1)他汀化合物；(2)酪蛋白激酶1抑制剂；(3)cAMP诱导剂；(4)组蛋白甲基转移酶抑制剂，以将体细胞转化为成骨细胞。
• Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
  申请人：Sawutz G. David

  公开号：US20060194845A1

  公开（公告）日：2006-08-31

  The present invention provides methods of increasing muscle tissue in animals. In one aspect of the invention, the method includes administering an effective amount of an ALK 5 receptor inhibitor such as to an animal for a time sufficient to cause the desired effect.

  本发明提供了增加动物肌肉组织的方法。 在本发明的一个方面中，该方法包括向动物施用有效量的 ALK 5 受体抑制剂，如施用时间足以引起所需的效果。
• TRIARYLIMIDAZOLES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1169317A1

  公开（公告）日：2002-01-09